Continuous Oxytocin Infusion Versus Pulsatile Intravenous Oxytocin for Augmentation of First Stage of Labor
NCT ID: NCT02723461
Last Updated: 2016-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2016-03-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor
NCT04017247
Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study
NCT02859571
Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery
NCT02080104
Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor
NCT02680938
Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor
NCT05782816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The required sample size has been calculated using the IBM© SamplePower© Software (IBM© Corp., Armonk, NY, USA). A previous study by Tribe et al., 2012 reported that the mean infusion to delivery time associated with continuous infusion of oxytocin was 7.17 hours with a 95% confidence interval (95% CI) of 6.58 to 7.77 hours versus 9.61 hours (95% CI, 8.95 to 10.27 hours) in association with pulsatile oxytocin. The sample size for either regimen in that study was 240 patients or 241 patients, respectively. From the study of Tribe et al. (2012), it could be estimated that the standard deviation (SD) for the infusion to delivery time was 4.66 hours or 5.23 hours for the continuous or pulsatile oxytocin regimen, respectively. This calculation is derived from solving any of the following equations for the SD given the mean, lower or upper 95% CI limit, and sample size:
Lower 95% CI limit = mean - (1.96 \* SD / √n)..... Equation 1 Upper 95% CI limit = mean + (1.96 \* SD / √n…..Equation 2 where SD is the standard deviation and n is the sample size (Chow et al., 2003).
So, it is estimated that a sample size of 66 patients in either study group (total, 132 patients) would achieve a power of 80% (type II error, 0.2) to detect a statistically significant difference between the two groups as regards the infusion to delivery time using a two-side unpaired Student t test with a confidence level of 95% (type I error, 0.05). the mean ± SD infusion to delivery time in both groups is assumed to be identical and to equal 9.61 ± 5.23 hours under the null hypothesis. Under the alternative hypothesis, the mean ± SD infusion to delivery time is assumed to equal 7.17 ± 4.66 hours in the continuous infusion group versus 9.61 ± 5.23 hours in the pulsatile group.
This sample size of 66 patients in each study group would have a power of 93% (type II error, 0.07) to detect a statistically significant difference between the two groups as regards the rate of successful induction of labor for a medium effect size (w) of 0.3 using a two-sided chi-squared test with a confidence level of 95% (type I error, 0.05). The effect size (w) is calculated as follows:
w =√(χ\^2/N), where χ2 is the chi-squared statistic and N is the total sample size. (Chow et al., 2003).
Following admission, all patients will undergo complete clinical examination and detailed medical history will be obtained as follows:
A. Personal history. B. Obstetric history: where the gestational age will be calculated by the date of last menstrual period or by ultrasonography in unreliable dates.
C. Gynecological history.
Grouping:
The patients needing augmentation of first stage of labor will be divided equally into two groups:
Group 1 (study group ; 60 patients ) :
Patients at labor are given augmentation by oxytocin in pulsatile method
Group 2 (control group ;60 patients) :
Patients at labor are given augmentation by oxytocin in continuous method
Intervention:
Pulsatile group:
Pulsatile infusion protocol using a programmable syringe pump is applied .The pulsatile regime, oxytocin (Syntocinon,stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) will be doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
Continuous group :
Continuous group will be administrated oxytocin (Syntocinon,stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10minutes).
Then each patient will have case record form in which the following data will be recorded:
1. Patient initials.
2. Study number.
3. Group.
4. Parity.
5. Gestatinal age ( first day of last menstrual period - early ultrasound).
6. Rupture of membranes.
7. Duration of rupture of membranes.
8. Duration of first stage of labour.
9. Duration of second stage of labour.
10. Need for instrumental delivery.
11. Need for Cesarean section.
12. Adverse effect.
13. Neonatal outcome.
14. Maternal complications.
15. Adverse effect related to oxytocin.
16. Total dose of oxytocin infused.
17. Previous complicated vaginal delivery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pulsatile oxytocin
Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
Pulsatile Oxytocin
Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
continuous oxytocin
Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Continuous Oxytocin
Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pulsatile Oxytocin
Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Continuous Oxytocin
Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Single viable fetus.
3. Rupture of membranes before augmentation of labor.
4. Cephalic presentation.
5. Term pregnancy.
Exclusion Criteria
2. Induction of labor by prostaglandins.
3. Any uterine previous surgery.
4. Fetal anomalies.
5. Premature labor.
6. Previous cesarean section.
7. Any uterine anomalies.
8. Multiple pregnancy.
17 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams Maternity Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Ahmed Mahmoud Riad
Lecturer of obstetrics and gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams maternity hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
pulsatile oxytocin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.